Trial Profile

An Open-label Study in Healthy Participants to Assess the Pharmacokinetics of AZD0780 When Administered Alone and in Combination With Itraconazole or Carbamazepine, and to Assess the Pharmacokinetics of Midazolam, and Ethinyl Estradiol/Levonorgestrel When Administered Alone and in Combination With AZD0780

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 06 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AZD 0780 (Primary) ; Carbamazepine; Ethinylestradiol/levonorgestrel; Itraconazole; Midazolam
Indications Dyslipidaemias
Focus Pharmacokinetics
Sponsors AstraZeneca

27 Apr 2025 Status changed from recruiting to completed.
27 Feb 2025 The number of arms increased from 2 to 4, with the addition of new drugs, midazolam and ethinyl estradiol/levonorgestrel. Part 3, part 4, primary endpoints AUCin, AUClast and Cmax added newly.
27 Feb 2025 Planned number of patients changed from 42 to 78.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com